Knowledge Hub

Global COPD Market Increasing Prevalence Of Diseases Boosts

Press Release   •   Feb 06, 2017 05:27 EST has added a report to its database on the pharmaceutical industry. The report, titled “COPD Therapeutics In Major Developed Markets To 2021 - Emergence Of Addition-In-Class And First-In-Class Products Offsets Sales Erosion Of Leading Brands” analyzes the dynamics of the global COPD market in order to provide valuable information on the prevailing competitive landscape and scope of growth in the near future.

The global market for chronic obstructive pulmonary disease (COPD) is associated with the provision of drugs and therapeutic products for those suffering from this ailment. COPD is a progressive and chronic inflammation of the lungs and its airways.

The global COPD market currently holds 203 products that are actively in the development stage. This does not include 4 products whose stages of development are currently unknown. The report explains that a majority of the pipeline products in the global COPD market belong to the known and trusted brands, while there is a line of novel, first-in-class drugs. These type of treatments are extremely crucial in gauging medicine’s understanding of COPD.

According to the report, the global COPD market will exhibit a CAGR of 2.9% till 2021. The market was valued at US$9.2 bn in 2014. By the end of 2021, the global COPD market will be valued at US$11.2 bn.

The report further states that the high rate of attrition in the global COPD market trials is creating a restraint in its growth rate. The current attrition rate of COPD trials is 89.6%.

For Sample Copy, click here:

The report provides historical relevancies to the global COPD market in order to fully realize the future of the market. For instance, the report states that since 2006, there have been 59 licensing deals and 41 deals for COPD products co-development.

The report provides a wide-angled scope of the global COPD market, citing multiple additions that have benefitted the market in the recent past.

Some of the key aspects of the global COPD market discussed in the report include the drug classes that dominate the market, the newly-approved COPD therapies and their value addition to the market, and a direct comparison of the leading market therapies from a clinical point of view.

Other areas included in the report are the identification of the molecular targets that can be placed in the pipeline with the highest frequency, the placement of new therapies in the global COPD market, and the failure rates in the clinical development of individual phases.

COPD creates multiple health problems such as difficulty in breathing and repeated exacerbations of symptoms, which makes it one of the leading lung-related causes of morbidity. COPD is the fifth-largest cause of death globally. It is caused primarily due to tobacco smoke and environmental pollutants.

A large number of pharmaceutical products are available for the treatment of COPD. However, none of the treatments show any kind of long-term action against the progressive disease.

To order report Call Toll Free: 866-997-4948 or send an email on